Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) COO Eric Venker sold 434,478 shares of Roivant Sciences stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $10.82, for a total transaction of $4,701,051.96. Following the sale, the chief operating officer now directly owns 1,127,290 shares in the company, valued at $12,197,277.80. The trade was a 27.82 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Eric Venker also recently made the following trade(s):
- On Thursday, March 20th, Eric Venker sold 315,522 shares of Roivant Sciences stock. The stock was sold at an average price of $11.06, for a total transaction of $3,489,673.32.
- On Thursday, February 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $10.65, for a total value of $1,065,000.00.
- On Thursday, February 13th, Eric Venker sold 218,041 shares of Roivant Sciences stock. The stock was sold at an average price of $10.42, for a total value of $2,271,987.22.
- On Tuesday, January 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.28, for a total transaction of $1,128,000.00.
- On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The stock was sold at an average price of $11.54, for a total transaction of $2,050,704.16.
- On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The stock was sold at an average price of $11.82, for a total transaction of $2,090,958.00.
Roivant Sciences Stock Down 1.3 %
Shares of NASDAQ ROIV traded down $0.14 during midday trading on Friday, hitting $10.35. The stock had a trading volume of 871,987 shares, compared to its average volume of 5,534,777. The business's 50 day moving average is $10.76 and its 200-day moving average is $11.43. Roivant Sciences Ltd. has a 52 week low of $9.96 and a 52 week high of $13.06. The company has a market cap of $7.38 billion, a P/E ratio of -68.96 and a beta of 1.26.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. As a group, analysts expect that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.
Institutional Investors Weigh In On Roivant Sciences
Several institutional investors have recently modified their holdings of ROIV. Norges Bank purchased a new position in Roivant Sciences in the 4th quarter worth about $52,443,000. TOMS Capital Investment Management LP bought a new stake in shares of Roivant Sciences in the third quarter worth approximately $46,333,000. Invesco Ltd. raised its holdings in shares of Roivant Sciences by 49.7% during the fourth quarter. Invesco Ltd. now owns 9,515,058 shares of the company's stock valued at $112,563,000 after purchasing an additional 3,159,603 shares during the last quarter. FMR LLC lifted its position in Roivant Sciences by 5.6% during the third quarter. FMR LLC now owns 49,145,056 shares of the company's stock valued at $567,134,000 after purchasing an additional 2,593,910 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in Roivant Sciences by 5.8% in the fourth quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company's stock worth $521,553,000 after purchasing an additional 2,404,232 shares during the last quarter. 64.76% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on the stock. Cantor Fitzgerald upgraded shares of Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and set a $18.00 price objective on shares of Roivant Sciences in a research report on Tuesday, February 11th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Roivant Sciences has a consensus rating of "Buy" and a consensus target price of $17.10.
Get Our Latest Research Report on ROIV
Roivant Sciences Company Profile
(
Get Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Read More
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
